$JNJ

Over 100 pharmaceutical companies compete to develop 120+ NSCLC pipeline drugs, with 30+ in late-stage trials. Precision oncology advances drive innovation in biomarker-selected populations.

U.S. cardiovascular devices market projected to nearly double to $41.29B by 2032, driven by aging demographics and AI-powered tools.

MeiraGTx reacquires J&J's eye disease drug bota-vec for $25M, raises $100M in funding, targeting 2027 launch. Stock falls 15.8%.

Global ambulatory surgical equipment market projected to double from $7.39B in 2026 to $14.58B by 2035, driven by demand for minimally invasive procedures.

MeiraGTx acquires J&J's bota-vec gene therapy for rare blindness in $25M deal, targeting 2027 launch with promising Phase 3 clinical data.

J&J reported 9.9% Q1 revenue growth with raised guidance, though EPS fell 2.5% due to patent losses. Technical setup suggests 20% upside potential supported by strong pipeline expectations.

Johnson & Johnson beat Q1 earnings expectations with 9.9% revenue growth driven by oncology products, but free cash flow plummeted 55.6% year-over-year.

Mestag Therapeutics' FAP-targeted bispecific antibody MST-0312 selected for late-breaking AACR presentation in April 2026, with Phase 1 trials expected to begin mid-year.

Eli Lilly reports fourth positive Phase 3 trial for Jaypirca in chronic lymphocytic leukemia, positioning drug for label expansion ahead of competitive launches.

S&P 500 dividend yields fall to 1.2% lows, but AbbVie, Procter & Gamble, and Coca-Cola offer yields of 3.20%, 2.91%, and 2.66% respectively.

CSPC market projected to surge from $5.14B (2025) to $11.75B (2036), driven by aging populations, new drug approvals, and emerging therapies.

Bristol Myers Squibb trades at attractive 9.5x forward P/E with 4.2% yield and 17 years of dividend hikes, but faces revenue declines and patent expiration risks.

S&P 500 rallies 3.6% as Netflix emerges as a buy ahead of strong earnings, while J&J faces downgrades and patent cliff pressures triggering a sell recommendation.

Nvidia's CUDA platform with 100M+ installations creates unmatched switching costs, not just its AI chips. Stock trades at 21x forward earnings after 73% quarterly growth.

Major indexes surged 2.5%+ following Iran ceasefire announcement. Experts recommend quality stocks, Dividend Kings, and undervalued AI equities for disciplined investors.

Crohn's Disease drug market projected to grow 45% to $13.8B by 2032, driven by eight new therapies with novel mechanisms of action reshaping competition.

Johnson & Johnson's 63-year dividend streak and AAA rating offer security, but 2.2% yield falls short of 4% income targets, requiring complementary holdings.

Martin Capital Partners exits $4.5M Robert Half position as $RHI stock plunges 44.6% amid staffing sector weakness and cooling corporate hiring.

Microsoft erases 140.4 basis points from S&P 500 returns in 2026, while energy giants like Exxon Mobil emerge as top performers, shifting market dynamics away from Big Tech.

President Trump's executive order imposes 100% tariffs on imported drugs, exempting 13 companies with MFN agreements and U.S. manufacturing commitments through 2029.